| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
CGRP1 receptor[1]
CGRP1 receptor (Calcitonin Gene-Related Peptide 1 receptor). Also interacts with CLR/RAMP complexes. |
|---|---|
| ln Vitro |
Adrenomedullin(1-50), a peptide consisting of 50 amino acids, selectively dilates blood vessels by activating the CGRP1 receptor[1].
Adrenomedullin (1-50) stimulates the generation of nitric oxide (NO) and hydrogen sulfide (H2S) in hypoxic rats. This activity helps control the development of hypoxic pulmonary hypertension and pulmonary vascular structural remodeling in vitro. |
| ln Vivo |
Rat adrenalomedullin (1–50) stimulates the arterial mesenteric vasculature to vasodilate in a dose-dependent and endothelium-independent manner; CGRP1 receptor antagonist blocks this action. The CGRP1 receptor in the rat's double-perfused mesenteric bed is activated by adrenalomedullin (1–50)[1]. Adrenomedullin (1-50) attenuates the structural remodeling of the pulmonary arteries in rats that are hypoxic and have elevated amounts of H(2)S and plasma NO. Adrenomedullin (1-50) stimulates the generation of NO and H(2)S in hypoxic rats, which in turn controls the development of hypoxic pulmonary and hypertension hypoxic pulmonary vascular structural remodeling[2].
Rat Adrenomedullin (1-50) induces a potent and selective, endothelium-independent arterial vasodilation in the mesenteric arterial bed. It also ameliorates pulmonary vascular structural remodeling in hypoxic rats by increasing plasma NO and H2S concentrations. |
| Enzyme Assay |
For a receptor binding assay, rat lung or mesenteric artery membranes are incubated with [125I]-hCGRP (a known ligand for CGRP1 receptors) in the presence of unlabeled rat Adrenomedullin (1-50). After incubation, bound radioactivity is separated by filtration to determine the IC50/Ki.
|
| Cell Assay |
Rat primary astrocytes or NG108-15 cells are seeded and treated with varying concentrations of rat Adrenomedullin (1-50). The cytosolic free calcium concentration is measured using a fluorescent indicator (e.g., Fura-2-AM). The peptide does not raise calcium, confirming it acts via a distinct cAMP-coupled pathway.
|
| Animal Protocol |
To study vascular effects, male Wistar rats are anesthetized, and the mesenteric arterial bed is isolated and perfused. Rat Adrenomedullin (1-50) is injected into the perfusion line. The perfusion pressure is recorded; a drop in pressure indicates vasodilation. The effect is blocked by a CGRP1 antagonist.
|
| ADME/Pharmacokinetics |
As a 50-amino acid peptide, rat Adrenomedullin has a very short plasma half-life (minutes) due to rapid degradation by proteases and clearance. For in vivo research, it is typically administered via continuous intravenous infusion to maintain stable, therapeutic levels for hemodynamic studies.
|
| Toxicity/Toxicokinetics |
No specific toxicity data is reported for this research peptide. At high doses, the potent vasodilatory effect can cause severe hypotension and cardiovascular collapse. This product is strictly for research purposes and is not intended for human therapeutic or diagnostic use.
|
| References |
|
| Additional Infomation |
Adrenomedullin was first discovered in rat pheochromocytoma cells. The rat (1-50) sequence is highly conserved across species. It is the most potent endogenous vasodilator peptide known. The peptide's effects are mediated by a receptor complex comprising the calcitonin receptor-like receptor (CLR) and receptor activity-modifying proteins (RAMPs). It is a research tool for studying vascular biology.
|
| Molecular Formula |
C242H381N77O75S5
|
|---|---|
| Molecular Weight |
5729.50
|
| Appearance |
Solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 0.1745 mL | 0.8727 mL | 1.7454 mL | |
| 5 mM | 0.0349 mL | 0.1745 mL | 0.3491 mL | |
| 10 mM | 0.0175 mL | 0.0873 mL | 0.1745 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
